The inhibitors of apoptosis (IAPs) constitute a family of proteins involved in the regulation of various cellular processes, including cell death, immune and inflammatory responses, cell proliferation, cell differentiation, and cell motility. There is accumulating evidence supporting IAP-targeting in tumors: IAPs regulate various cellular processes that contribute to tumor development, such as cell death, cell proliferation, and cell migration; their expression is increased in a number of human tumor samples, and IAP overexpression has been correlated with tumor growth, and poor prognosis or low response to treatment; and IAP expression can be rapidly induced in response to chemotherapy or radiotherapy because of the presence of an internal ribosome entry site (IRES)-dependent mechanism of translation initiation, which could contribute to resistance to antitumor therapy. The development of IAP antagonists is an important challenge and was subject to intense research over the past decade. Six molecules are currently in clinical trials. This review focuses on the role of IAPs in tumors and the development of IAP-targeting molecules for anticancer therapy.
Introduction: IAP family of proteins
The inhibitors of apoptosis (IAPs) constitute a family of proteins highly conserved throughout evolution. IAPs were initially discovered in baculoviruses two decades ago, 1 as potent inhibitors of apoptosis in infected insect cells. The first human homologous neuronal apoptosis inhibitory protein (NAIP) and cellular IAP 1 and 2 (cIAP1 and cIAP2) were characterized 2 years later, 2, 3 followed by X-chromosome linked IAP (XIAP), 4 ,5 survivin, 6 Apollon (also called BRUCE), 7 melanoma IAP (ML-IAP) (also called Livin), 8 and IAP-like protein 2 (ILP2). 9 The IAP family is defined by the presence of one to three conserved protein motifs named a baculoviral IAP repeat (BIR). Most of them form a surface hydrophobic groove that specifically binds a conserved tetrapeptide motif, called IAP binding motif (IBM), found in the active subunits of apoptotic protease caspase-3, -7, and -9 and in cellular IAP antagonists, such as the second mitochondria-derived activator of caspases (Smac) (also named direct IAP-binding protein with low isoelectric point (pI) [DIABLO]) [10] [11] [12] [13] and the high temperature requirement protein A2 (HtrA2) 12, 14 ( Figure 1 ). The first BIR of XIAP and cIAPs does not bind IBM but rather, the signaling molecule transforming growth factor beta (TGFβ)-activated kinase 1-binding protein 1 (TAB1) 15 or the tumor necrosis factor (TNF) receptor (TNFR) associated factors (TRAFs), [16] [17] [18] connecting XIAP and cIAPs with the TGF and TNF signaling pathways, respectively. In addition to the BIRs, cIAPs, XIAP, ML-IAP and ILP2 also possess a C-terminal RING (really interesting new gene) domain conferring an E3 ligase activity in the ubiquitination or neddylation 19 reactions (for review, 20, 21 ). Numerous partners of IAPs have been identified, including some caspases, [22] [23] [24] some signaling molecules, 25, 26 some regulators of the NF-κB: nuclear factor of kappa-light polypeptide gene enhancer in B-cell activating pathways, 25 some regulators of the actin cytoskeleton, 27 and some transcriptional regulators. 28, 29 Thus, although they were initially characterized as inhibitors of apoptosis, IAPs display additional nonapoptotic functions in the regulation of cell proliferation, cell division, cell differentiation, cell motility, and in proinflammatory and immune response (for review, 25, 26 ),which could contribute to oncogenesis.
Expression of IAPs in tumors
The expression of IAPs or cellular IAP antagonists such as Smac, 11 HtrA2, or the septin-like mitochondrial protein, ARTS, 30, 31 were shown to be altered in a number of human tumor samples ( Table 1 ). Overexpression of IAPs or downregulation of the cellular IAP antagonists have been correlated with advanced progressive disease, aggressiveness, and poor prognosis or low response to treatment (Supplementary Table S1 ). The alterations of IAP expression can be associated or not, with gene mutations. The baculoviral IAP repeat containing protein (BIRC)2 and BIRC3 genes, encoding cIAP1 and cIAP2, respectively, are located on chromosome 11q21-22, a region found amplified in human hepatocarcinoma, 32 mammary carcinoma, 33 medulloblastoma, 34 and in pancreatic, 35 cervical, 36 lung, 37 oral squamous cell, 38 and esophageal 39 carcinomas. Some (30%) mucosa-associated lymphoid tissue (MALT) lymphoma are associated with the chromosomal translocation t(11;18) (q21;q21) generating a chimeric protein composed of the N-terminal sequences of cIAP2 fused to the C-terminal sequence of MALT1. 17, 40 Conversely, IAPs can also display antitumoral properties in lymphocytes. The BIRC2 and/or BIRC3 genes were found to be mutated in some multiple myeloma samples, 41, 42 and the BIRC4 encoding XIAP in X-linked lymphoproliferative disease. 43 The expression and functions of the atypical IAP survivin in tumors, and the development of specific survivin-targeted therapy were recently reviewed by Coumar et al 44 and won't be discussed here.
Role of IAPs in cancer IAPs as apoptotic regulators
IAPs were first characterized as inhibitors of apoptosis because of their ability to bind caspases. Indeed, cIAPs, XIAP and ML-IAP can bind caspase-3, -7, and -9 via the BIRs 10, 11, 45, 46 and can induce their ubiquitination or neddylation via the RING domain. 19, [22] [23] [24] The influence of the ubiquitination is still not very well established, triggering degradative or nondegradative consequences, [22] [23] [24] while the neddylation of caspase-7, by XIAP, inhibits its activity. 19 In addition, XIAP is able to directly inhibit the enzymatic activity of caspases ( Figure 1 ). The XIAP BIR3 binds the dimer interface of caspase-9, and the linker region upstream of BIR2 binds across the substrate binding pocket of caspase-3 and -7, which hinder substrate accessibility and hide the catalytic residue of caspases. [47] [48] [49] The capacity of XIAP to inhibit caspase activity could account for the resistance of cancer cells to antitumor therapy. Indeed, DNA-damaging treatments, such as ionizing irradiations, induce a translational upregulation of XIAP as a consequence of the presence of an internal ribosome entry site (IRES)-dependent translation mechanism, which results in the resistance of carcinoma cells to radiation-induced apoptosis. 50, 51 IAPs can also inhibit cell death at an earlier step, preventing the assembly of caspase-8-or -10-activating platforms. Caspase-8 and -10 are initiator caspases recruited . cIAPs trigger self-ubiquitination and ubiquitination of RIP1. These ubiquitin chains serve as a scaffold for the recruitment of IKK, TAK, and LUBAC. Once activated, IKK complex triggers phosphorylation of IκBα, which is then degraded by the UPS and releases NF-κB dimer, which promotes the transcription of target genes. In the noncanonical pathway of NF-κB activation, cIAPs promote the degradative ubiquitination of NIK and associated TRAF proteins and prevent the activation the IKK complex required for transcription factor activation. On the other hand, cIAPs and XIAP prevent the assembly of RIP1-containing initiator caspase-activating complexes, named complex-II and Ripoptosome; and XIAP inhibits, through a direct interaction via BIR2 and BIR3, the activity of caspase-3, -7, and -9. SMs bind to the BIR domains of cIAPs and stimulate their E3-ubiquitine ligase activity. This results first, in the ubiquitination of RIP1, leading to the canonical NF-κB activation, and second, in the rapid autoubiquitination and subsequent proteasome-mediated degradation of cIAPs. Depletion of cIAPs releases NIK, resulting in the noncanonical activation of NF-κB, and NF-κB target gene expression, including TNFα, MCP-1, and IL-6. TNFα engages TNFR1 via an autocrine pathway. In the absence of cIAP1, stimulation of TNFR1 triggers the assembly of the secondary RIP1-containing cytoplasmic complex (complex II), leading to cell death. SM-mediated IAP depletion can also favor the formation of the Ripoptosome, leading to cell death. Abbreviations: BIR, baculoviral IAP repeat; cIAP, cellular IAP; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; IAPs, inhibitors of apoptosis; IL, interleukin; IKK, IκB kinase complex; LUBAC, linear ubiquitin chain assembly complex; MCP-1, monocyte chemoattractant protein; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; NIK, NF-κB-inducing kinase; RIP1, receptor interacting protein 1; SM, Smac mimetic; Smac, second mitochondria-derived activator of caspases; TAK, TGFβ-activated kinase; TGFβ, transforming growth factor beta; TNF, tumor necrosis factor; TNFR1, tumor necrosis factor receptor 1; TRADD, TNFR1-associated death domain; TRAF, TNFR associated factor; UBA, ubiquitin proteasome system; XIAP, X-chromosome linked IAP; TAB,TAK1-binding partners; HOIL, heme-oxidized IRP2 ligase-1; HOIP, HOIL-1L-interaction protein; NEMO, nuclear factor-κB (NF-κB) essential modulator; UPS, ubiquitin-proteasome system.
by the adaptor Fas-associated death domain protein (FADD) in multiprotein complexes, which provide the proximity required for caspase homodimerization and self-activation (for review, 52 ). These molecular platforms are assembled either in response to the engagement of death receptor from the TNFR superfamily (in which case, these are referred to as death-inducing signaling complex [DISC] and complex II) 52, 53 or in response to genotoxic stress, tumor necrosis factor-like weak inducer of apoptosis (TWEAK) engagement, or toll-like receptor (TLR) 3 stimulation (in which case, they are referred to as Ripoptosome). 54, 55 Complex II 50,51 and Ripoptosome 52, 53 share, in addition to the caspase and the adaptor FADD, the serine/threonine kinase receptor interacting protein (RIP) ( Figure 2 ). cIAPs and XIAP are potent regulators of proteins from the RIP family, catalyzing the conjugation of ubiquitin chains that control either protein degradation or signal transduction pathways [56] [57] [58] [59] [60] [61] [62] ( Figure 2 ). In the absence of cIAPs, non-ubiquitinated RIP1 promotes (through its kinase submit your manuscript | www.dovepress.com Dovepress Dovepress activity) the assembly of the caspase-activating platforms that leads to cell death 56, 62 ( Figure 2 ). Thus, cIAPs inhibit RIP1-containing caspase-activating platform assembly, either by promoting the ubiquitin-proteasome-mediated degradation of the components of the Ripoptosome 54 or by inducing a nondegradative ubiquitination of RIP1, which inhibits the cell death complex assembly and promotes survival-signaling pathway transduction. 56, 59, 63 IAPs as cell-signaling regulators
The role of IAPs in the regulation of the NF-κB-activating signaling pathways is well documented (for review, 25, 26 ). NF-κB is a transcription factor induced by the stimulation of antigen or cytokine receptors, by the recognition of microbiological patterns by the TLRs, the nucleotide-binding oligomerization domain-containing proteins (NODs), or the NOD-like receptors (NLRs), or in response to intracellular injuries, such as DNA damage or reactive oxygen species. NF-κB contributes to the adaptive response of cells, by mediating the expression of the proinflammatory molecules that counter microbial invasion and by promoting the expression of genes involved in cell survival, cell differentiation, and cell proliferation. 64 The transcription factor consists of heterodimers formed by one Rel subunit (RelA [also called p65], RelB, or c-Rel) and one NF-κB subunit (the p50 subunit of NF-κB1 or the p52 subunit of NF-κB2). In resting cells, the p50/RelA dimer is sequestered into the cytoplasm by the inhibitor of κB (IκB) proteins. Upon stimulation of the cell surface or intracellular receptors, or DNA damage, p50/RelA is released as a consequence of the degradation of NF-kappa-B inhibitor alpha (IκB-α) and translocated into the nucleus to stimulate proinflammatory gene transcription ( Figure 2 ). Degradation of IκB-α requires its phosphorylation by the IκB kinase (IKK) complex, which is activated by ubiquitination by the linear ubiquitin chain assembly complex (LUBAC) and by phosphorylation by TGFβ-activated protein kinase 1 (TAK1) 64 ( Figure 2 ). cIAPs and XIAP promote the steric proximity of TAK1, LUBAC, and IKK complex. In the TNF-R1-signaling pathway, cIAPs are recruited along with RIP1 to the receptor 61 and trigger self-ubiquitination and the nondegradative polyubiquitination of RIP1 56, 57, 66 ( Figure 2) , and in NOD2-mediated inflammatory signaling, XIAP and cIAPs mediate the conjugation of ubiquitin chains to RIP2. [67] [68] [69] These ubiquitin chains serve as a scaffold for the recruitment and activation of the signaling complexes leading to IKK activation 56, 61, 68, 70 ( Figure 2 ). cIAPs can also modulate NF-κB activation by catalyzing the monoubiquitination of the IKK component NF-κB essential modulator (NEMO), which is required for IKK activation, 71, 72 and XIAP promotes the activation of TAK1 and the steric proximity of TAK1 and IKK complex 71 during TGFβ and myelin basic protein (MBP) receptor signaling, or in response to DNA damage. 15, 71, [73] [74] [75] A second NF-κB-activating signaling pathway, named the noncanonical pathway, involves NF-κB-inducing kinase (NIK), which catalyzes the phosphorylation of IKKα. In turn, IKKα induces the phosphorylation of the p100 NF-κB2 precursor, leading to its proteolytic activation into active p52 NF-κB2 (Figure 2) . cIAPs prevent the noncanonical activation of NF-κB by mediating the ubiquitination and the proteasomal-mediated degradation of NIK 70, [76] [77] [78] [79] (Figure 2 ). Mutations in cIAP-encoding genes leading to NIK stabilization and chronic NF-kB activation could facilitate B cell malignancy and lymphomagenesis, as observed in some multiple myelomas that harbor mutations in the cIAP1-or cIAP2-encoding genes 41, 42 and as observed in MALT lymphoma that is associated with a chromosomal translocation t(11;18)(q21;q21), generating a chimeric protein composed of the N-terminal sequence of cIAP2 fused to the C-terminal sequence of MALT1. 17, 40, 80 Cell proliferation and migration cIAPs are positive regulators of cell proliferation, a function correlated with the nuclear localization of the proteins. 29, 81 Interestingly, the nuclear expression of cIAP1 has been associated with advanced disease stages and poor patient prognosis in human cervical and esophageal squamous cell carcinomas and bladder cancers 36, 82, 83 (Supplementary  Table S1 ). The influence of IAPs on cell proliferation can be explained by their capacity to stimulate the activity of the c-Myc and E2F1 transcription factors, which are important regulators of cell cycle progression and cell proliferation with oncogenic properties. 28, 29 IAPs have also been involved in the regulation of the invasive properties of mammalian cancer cells, as recently reviewed. ). In the trials, AEG35156 appeared to accumulate in the liver and to have efficiently downregulated XIAP messenger ribonucleic acid (mRNA) in peripheral blood mononuclear cells and hepatocytes. AEG35156 is generally well tolerated except when administered in repeated high doses. Promising results were obtained with AEG35156 used as a single agent in solid tumors 88 and in combination with cytarabine and idarubicin in AML 89 in the Phase 1 studies, but it failed to show any significant antitumoral activity in the randomized Phase 2 studies in pancreatic adenocarcinoma, when combined with Gemcitabine, 90 or in AML, when it was given in combination with cytarabine and idarubicin. 91 The structural characterization of the interaction of XIAP with caspases, or with Smac, or the drosophila Smac homologs has provided very potent tools for the design of synthetic IAP antagonists aiming to inhibit the capacity of XIAP to neutralize caspases. 11, [92] [93] [94] The surface hydrophobic groove of IAP BIRs binds the IBM found in the N-terminal of the active subunits of caspase-3, -7, and -9 and exposed by activating proteolytic processing. 10, 11 Cellular IAP antagonists also own an IBM. [10] [11] [12] [13] During the apoptotic process, the Smac IBM is exposed as a consequence of the cleavage of the mitochondria-targeting signal, and matured Smac is released from the mitochondria into the cytosol. [10] [11] [12] The tetrapeptide Ala-Val-Pro-Ile (AVPI) IBM motif of Smac inserts into the XIAP BIR2 and BIR3-caspase interaction pocket and abrogates XIAP-mediated caspase inhibition 93, 95, 96 ( Figure 1) . The Smac N-terminal peptide was also derived to produce cell permeable peptides and was shown to mimic the activity of Smac and to sensitize human cancer cell lines to diverse chemotherapeutic agents, including etoposide, teniposide, cisplatin, paclitaxel, 7-ethyl-10-hydroxycamptothecin (SN-38), and TRAIL agonists. [97] [98] [99] [100] In xenograft models, a Smacderived peptide, made permeable by linking to the shuttle peptide trans-activation of transcription (TAT) from HIV, enhanced the antitumoral effect of TRAIL in glioma, 99 and a polyarginine-conjugated Smac peptide was shown to sensitize non-small cell lung carcinoma cells to cisplatin, 98 with little toxicity to normal tissues. The pharmacological properties of such Smac-derived peptides were not good enough to merit consideration of these molecules as therapeutic agents; however, they provided the bases for the structure-based design of IAP antagonists named Smac mimetics (SMs). Several approaches were used, including the screening of peptide or peptidomimetic libraries, 101, 102 and the structure-based design of conformationally constrained SMs 103,104 ( Figure 3 ). Considerable efforts were invested to improve the affinity of the compounds to the IAP BIR domains, to improve their ability to antagonize IAPs, [104] [105] [106] [107] to improve cellular delivery and activity (ie, their capacity to induce apoptosis or to sensitize to apoptotic agents), and to improve their in vivo stability and bioavailability. The preclinical assays demonstrated their capacity to inhibit tumor growth in multiple solid tumors, 102, 107, 108 acute lymphoblastic leukemia (ALL), 108 and multiple myeloma 109 xenograft models and to sensitize cells to TRAIL, proteasome inhibitors, B-cell lymphoma protein 2 (Bcl-2) family-targeting compounds, and more conventional therapeutic agents, such as radiation, melphalan, or cisplatin. 103, [109] [110] [111] [112] [113] [114] Importantly, these compounds were well tolerated by animals and did not display toxicity against normal lymphocytes and bone marrow stromal cells 109 or normal mammary epithelial cells. 115 The analysis of binding affinity revealed that similarly to Smac, 93, 95, 96 SMs can bind to XIAP-BIR2, preventing XIAP-caspase-7 and -3 binding, and to XIAP-BIR3, abrogating the XIAP-mediated inhibition of caspase-9. Structural and biochemical studies of the apoptotic activity of Smac cellular protein revealed, first, that it forms a symmetric dimer; 93, 94 second, that 95 Overall, these observations support the conclusion that compounds targeting both BIR domains could be more efficient as XIAP antagonists and lead to the development of bivalent small molecules containing two Smac AVPI IBM motif mimetics. 117 As expected, these compounds appeared to be more potent than their monovalent counterparts, in antagonizing XIAP and in activating caspases. 104, 117, 118 Like the monovalent versions, the bivalent molecules either inhibited tumor growth or sensitized cells to both conventional and nonconventional anticancer therapies in the preclinical assays and did not display toxicity to normal human primary cells; 104, [117] [118] [119] [120] [121] however, unlike the monovalent molecules, the bivalent SMs are not orally bioavailable. To date, more than 50 applications for patents related to IAP antagonists have been filed (for review, 122 ), and six SMs have entered human clinical trials (http://www. clinicaltrials.gov/) for the treatment of cancer (described in Table 3 ).
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Mechanisms of action of SMs
As expected, SMs abrogate XIAP-mediated caspase inhibition and therefore increase caspase-3 and -7 activities (Figure 1 ). However, in addition to binding XIAP BIRs, SMs also bind the BIR domains of ML-IAP, cIAP1 and cIAP2. 56, 104, 105, 115, 118 SMs stimulate the E3-ubiquitine ligase activity of cIAPs, which results in the ubiquitination of RIP1, leading in turn, to canonical NF-κB activation and the rapid autoubiquitination and subsequent proteasome-mediated degradation of cIAPs [123] [124] [125] [126] (Figure 2 ). Depletion of cIAPs abolishes the cIAP-mediated ubiquitination and degradation of NIK and induces canonical activation of NF-κB. In turn, NF-κB induces the expression of proinflammatory cytokines and chemokines, including TNFα, which can trigger cell death by an autocrine pathway. 66, [125] [126] [127] Furthermore, depletion of cIAPs favors the assembly of the RIP1-containing cytoplasmic cell death complexes, such as complex II and Ripoptosome, resulting in cell death in some sensitive cancer cells, or in the sensitization to TNFα or DNA-damaging chemotherapeutic agents 54, 55 ( Figure 2 ). SMs exert their activity through XIAP and cIAPs and both effects are required for their maximal antitumoral activity. [128] [129] [130] Indeed, IAP antagonists displaying a high and selective affinity for cIAPs over XIAP appeared less potent than pan-IAP antagonists in promoting cancer cell death 129 and in sensitizing cancer cells to TRAIL. 131 As a consequence of cIAP degradation and NF-κB activation, the administration of SMs such as LCL161, GDC-0152, and HGS1029, resulted in the upregulation of cytokines and chemokines, [132] [133] [134] including TNFα, monocyte chemoattractant protein (MCP)-1, interleukin (IL)-7, IL-6, and interferon (IFN)γ. 134 MCP-1 was used as a clinical biomarker for SMs efficiency in clinical programs. 133, 135 The analysis of the proinflammatory characteristics of cellular Smac-induced cell death suggests that the proinflammatory response elicited by SMs could activate the adaptive antitumor immune response in cancers. 136 In dogs, intravenous (IV) administration of GDC-0152 induced an acute systemic inflammatory response with lung and hepatic injury, which are consistent with TNF-α mediated toxicity; 134 however, a similar TNF-α-driven inflammatory response was not observed in humans. 133 Although the first clinical trials did not reveal extensive toxicity of SMs when orally or intravenously administered, additional analysis of the consequences of cytokine and chemokine secretion are required. Because osteoclast differentiation and function are stimulated by activation of the noncanonical NF-κB pathway and because osteoclasts are susceptible to TNFmediated death, Yang et al analyzed the influence of SMs on bone metastasis and demonstrated that SMs stimulated osteoporosis and specifically enhanced metastasis in bone.
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Conclusion
SMs are a very promising new class of anticancer therapeutics. Results from preclinical studies have demonstrated an acceptable safety profile and some signs of antitumoral activity, in their use as a single agent or in combination with conventional or nonconventional therapies, such as dead receptor agonists, Bcl-2, or kinasetargeting therapies. The first clinical trials demonstrated a good tolerance and target inhibition. Ongoing and future clinical trials will determine the safety, appropriate indications, and drugs combinations. It will be important to determine the level and the site of production of TNFα and other cytokines and the consequences of cytokine production for tumoral and non-tumoral cells. Since IAPs are involved in the regulation of various cellular functions, it will be interesting to target specific IAP functions in order to limit possible adverse impacts. The consequences of SMs on the immune system in vivo and the use of cIAPs as potential therapeutic targets for inflammatory or immune disorders are still important questions that need to be addressed. 
